Company Overview
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.27.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +25.00% |
| 6 Months: | +36.23% |
| 3 Months: | -17.69% |
| 1 Month: | +7.80% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.80 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AVIR Atea Pharmaceuticals, Inc. R2K | 4.70 | -2.23 | $376.13M | 0.00% | -65.67% | -52.58% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 65.98M | 60.39M | 32.81M | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.04M | 41.34M | 45.57M | 54.93M | 48.01M |
| Operating Income | - | - | -3.77M | -4.04M | -10.00M | -17.63M | 30.66M | 8.69M | -22.15M | -42.17M | -32.30M | -16.28M | -41.57M | -35.23M | -40.78M | -69.81M | -46.92M | -37.20M | -39.04M | -41.34M | -45.57M | -54.93M | -48.01M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -38.94M | -41.24M | -45.46M | -54.83M | -47.90M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -34.07M | -36.95M | -41.85M | -51.63M | -45.39M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 203.00K | 207.00K | 196.00K | -6.77M | 50.00K |
| Net Income | -2.19M | -3.55M | -3.63M | -3.99M | -9.99M | -17.62M | 30.71M | 1.54M | -28.19M | -42.08M | -31.34M | -8.07M | -35.47M | -28.18M | -33.14M | -63.17M | -40.52M | -31.15M | -34.27M | -37.16M | -42.05M | -44.87M | -45.44M |
| Diluted EPS | - | - | - | -0.40 | -0.99 | -1.74 | 0.34 | 0.02 | -0.34 | -0.51 | -0.38 | -0.10 | -0.43 | -0.34 | -0.40 | -0.75 | -0.48 | -0.37 | -0.40 | -0.44 | -0.53 | -0.57 | -0.57 |
| R&D Expense | - | - | 2.41M | 2.82M | 7.75M | 13.60M | 26.57M | 39.80M | 43.02M | 29.63M | 19.86M | 4.91M | 28.95M | 22.06M | 28.18M | 57.58M | 34.70M | 26.16M | 29.58M | 32.27M | 38.35M | - | 41.13M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 48.63M | 351.37M | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 130.65M | 164.16M | 192.95M | 180.89M |
| Operating Income | -9.48M | -14.61M | -11.03M | 138.38M | -130.65M | -164.16M | -192.95M | -180.89M |
| EBITDA | - | - | - | - | -130.39M | -163.75M | -192.53M | -180.47M |
| Interest Expense | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -119.50M | -134.94M | -167.46M | -164.51M |
| Tax Provision | - | - | - | - | -3.59M | 1.02M | 925.00K | -6.16M |
| Net Income | -9.06M | -14.03M | -10.95M | 121.19M | -115.91M | -135.96M | -168.38M | -158.35M |
| Diluted EPS | - | -1.39 | -0.51 | 1.37 | -1.39 | -1.63 | -2.00 | -1.94 |
| R&D Expense | 6.67M | 10.17M | 38.02M | 167.21M | 81.94M | 114.24M | 144.10M | 148.02M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 22.07M | 863.63M | - | 666.71M | 594.97M | 464.67M | 315.22M |
| Current Assets | - | - | - | - | - | 660.92M | 590.46M | 462.36M | 310.99M |
| Cash & Equivalents | - | 34.49M | 21.66M | 850.12M | - | 188.46M | 143.82M | 64.70M | 95.71M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 0 | - | - | - | - |
| Total Liabilities | - | - | 2.53M | 315.83M | - | 26.14M | 39.78M | 25.80M | 39.78M |
| Current Liabilities | - | - | 2.44M | 315.80M | - | 18.48M | 32.38M | 18.60M | 39.78M |
| Long Term Debt | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | 3.12M | 2.40M | 1.64M | 843.00K |
| Total Equity | -27.51M | -36.16M | -49.57M | 547.80M | - | 640.57M | 555.19M | 438.87M | 275.43M |
| Shares Outstanding | - | - | - | - | - | 83.29M | 83.44M | 84.46M | 78.13M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.91M | -12.83M | 296.73M | - | -120.98M | -85.39M | -135.50M | -132.03M |
| Investing Cash Flow | -12.00K | -2.00K | -26.00K | - | -455.41M | 40.30M | 56.10M | 188.79M |
| Financing Cash Flow | 27.48M | - | 531.75M | - | 370.00K | 257.00K | 267.00K | -25.75M |
| Capital Expenditure | -12.00K | -2.00K | -26.00K | -4.00K | -1.94M | - | - | - |
| Free Cash Flow | -7.92M | -12.83M | 296.71M | - | -122.92M | -85.39M | -135.50M | -132.03M |
| Net Change in Cash | - | - | - | - | -576.02M | -44.84M | -79.13M | 31.02M |
| Share Buybacks | - | - | - | - | - | - | 0 | 25.52M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -22.7% | 39.4% | - | - | - | - |
| Net Margin % | - | - | -22.5% | 34.5% | - | - | - | - |
| ROE % | 25.1% | 28.3% | -2.0% | - | -18.1% | -24.5% | -38.4% | -57.5% |
| ROCE % | - | -74.4% | -2.0% | - | -20.2% | -29.2% | -43.3% | -65.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.93% | 11.95M | $59.40M |
| 2 | Blackrock Inc. | 10.54% | 8.44M | $41.92M |
| 3 | BML Capital Management, LLC | 8.82% | 7.06M | $35.08M |
| 4 | Tang Capital Management, LLC | 6.02% | 4.81M | $23.93M |
| 5 | Vanguard Capital Management LLC | 4.06% | 3.25M | $16.13M |
| 6 | Bain Capital Life Sciences Investors, LLC | 2.95% | 2.36M | $11.73M |
| 7 | Two Sigma Investments, LP | 2.33% | 1.86M | $9.26M |
| 8 | Geode Capital Management, LLC | 2.18% | 1.75M | $8.69M |
| 9 | State Street Corporation | 2.12% | 1.69M | $8.42M |
| 10 | Acadian Asset Management. LLC | 1.98% | 1.58M | $7.87M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AVIR
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers AT-587 is a Potential First-in Class Treatment for Hepatitis E Virus, a Serious Liver Disease with No Approved Therapies Study …
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND Represent the First Global Phase 3 Head-to-Head Trials…
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
Atea Pharmaceuticals (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Additional Data Presented Demonstrate High In Vitro Antiviral Potency and In Vivo Efficacy for AT-587, Atea’s Potential First-in-Class Direct-Acting Antiviral for the Treatment of Hepatitis E VirusBOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- At…
Spotlight On Atea Pharmaceuticals And 2 Other Prominent Penny Stocks
Over the last 7 days, the market has risen 1.1%, with a notable 29% increase over the past year and earnings projected to grow by 17% annually. While penny stocks might seem like a term from bygone market eras, they continue to offer intrig…
AVIR — Frequently Asked Questions
What is the current share price of Atea Pharmaceuticals, Inc. (AVIR)?
As of 2026-07-14 21:23 PDT, Atea Pharmaceuticals, Inc. (AVIR) trades at $4.70 on NasdaqGS. Its 52-week range is $2.82 to $6.15.
What is the market capitalisation of AVIR?
Atea Pharmaceuticals, Inc. (AVIR) has a market capitalisation of $376.13M on NasdaqGS.
What is the P/E ratio of AVIR?
AVIR trades at a trailing price-to-earnings (P/E) ratio of -2.23. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.54.
What is the return on equity (ROE) of AVIR?
AVIR has a return on equity (ROE) of -52.58%. Its return on capital employed (ROCE) is -65.67%.
Is AVIR a good stock to buy?
This page provides a data-driven analysis of Atea Pharmaceuticals, Inc. (AVIR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.